HRP20031071A2 - Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury - Google Patents

Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury

Info

Publication number
HRP20031071A2
HRP20031071A2 HR20031071A HRP20031071A HRP20031071A2 HR P20031071 A2 HRP20031071 A2 HR P20031071A2 HR 20031071 A HR20031071 A HR 20031071A HR P20031071 A HRP20031071 A HR P20031071A HR P20031071 A2 HRP20031071 A2 HR P20031071A2
Authority
HR
Croatia
Prior art keywords
spinal
brain
treatment
receptor antagonists
nerve injury
Prior art date
Application number
HR20031071A
Other languages
English (en)
Inventor
Torsten Hoffmann
Alan John Nimmo
Andrew Sleight
Pierre Vankan
Robert Vink
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HRP20031071A2 publication Critical patent/HRP20031071A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20031071A 2001-07-10 2003-12-22 Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury HRP20031071A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01116812 2001-07-10
PCT/EP2002/007323 WO2003006016A2 (en) 2001-07-10 2002-07-03 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury

Publications (1)

Publication Number Publication Date
HRP20031071A2 true HRP20031071A2 (en) 2004-06-30

Family

ID=8178001

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20031071A HRP20031071A2 (en) 2001-07-10 2003-12-22 Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury

Country Status (24)

Country Link
US (3) US20030083345A1 (es)
EP (2) EP1621195A3 (es)
JP (1) JP2004536119A (es)
KR (1) KR100589106B1 (es)
CN (1) CN100346789C (es)
AR (1) AR037008A1 (es)
AU (1) AU2002328837B2 (es)
BR (1) BR0210893A (es)
CA (1) CA2451566C (es)
GT (1) GT200200143A (es)
HK (1) HK1068266A1 (es)
HR (1) HRP20031071A2 (es)
HU (1) HUP0401210A3 (es)
IL (1) IL159350A0 (es)
MX (1) MXPA04000278A (es)
NO (1) NO332847B1 (es)
NZ (1) NZ530107A (es)
PA (1) PA8549901A1 (es)
PE (1) PE20030238A1 (es)
PL (1) PL211246B1 (es)
RU (1) RU2304435C2 (es)
UY (1) UY27374A1 (es)
WO (1) WO2003006016A2 (es)
ZA (1) ZA200400138B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1303490T1 (sl) * 2000-07-14 2008-10-31 Hoffmann La Roche N-oksidi kot predzdravila NK 1 receptorskega antagonista 4-fenil-piridin derivatov
EP1643998B1 (en) * 2003-07-03 2007-08-29 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
MX2007000198A (es) 2004-07-06 2007-03-15 Hoffmann La Roche Proceso para la preparacion de derivados de carboxamida-piridina utilizados como intermediarios en la sintesis de antagonistas del receptor nk-1.
US20060030600A1 (en) * 2004-08-06 2006-02-09 Patrick Schnider Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia
AU2006218179B2 (en) * 2005-02-22 2010-12-23 F. Hoffmann-La Roche Ag NK1 antagonists
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
ATE425144T1 (de) * 2005-03-23 2009-03-15 Hoffmann La Roche Metaboliten für nk-i-antagonisten zur emesis
EP3208272B1 (en) 2005-11-08 2020-01-08 Vertex Pharmaceuticals Incorporated Heterocyclic modulators of atp-binding cassette transporters
US7671221B2 (en) 2005-12-28 2010-03-02 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US7754739B2 (en) 2007-05-09 2010-07-13 Vertex Pharmaceuticals Incorporated Modulators of CFTR
DE102007018151A1 (de) * 2007-04-16 2008-10-23 Günenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
EP2164840A2 (en) 2007-05-09 2010-03-24 Vertex Pharmaceuticals Incorporated Modulators of cftr
AU2008278273A1 (en) * 2007-07-19 2009-01-22 Adelaide Research & Innovation Pty Ltd Method for reducing intracranial pressure
RS55559B1 (sr) 2007-12-07 2017-05-31 Vertex Pharma Čvrste forme 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il) benzoeve kiseline
EA201070700A1 (ru) 2007-12-07 2011-06-30 Вертекс Фармасьютикалз Инкорпорейтед Способы получения циклоалкилкарбоксамидопиридинбензойных кислот
JP5523352B2 (ja) 2008-02-28 2014-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド Ｃｆｔｒ修飾因子としてのへテロアリール誘導体
GB0808747D0 (en) * 2008-05-14 2008-06-18 Glaxo Wellcome Mfg Pte Ltd Novel compounds
NZ602838A (en) 2010-04-07 2015-06-26 Vertex Pharma Pharmaceutical compositions of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid and administration thereof
BR112015032534B1 (pt) * 2013-07-02 2020-03-03 Eustralis Pharmaceuticals Limited (Trading As Pressura Neuro) Uso de compostos ou sal ou solvato farmaceuticamente aceitável dos mesmos
EP3016658A4 (en) * 2013-07-02 2017-03-15 Eustralis Pharmaceuticals Limited (Trading as Pressura Neuro) Method for preventing and/or treating chronic traumatic encephalopathy-iv
MX370176B (es) * 2013-07-02 2019-12-04 Eustralis Pharmaceuticals Ltd Trading As Pressura Neuro Método para el tratamiento y/o prevención contra encefalopatia traumática cronica grado i.
CN105745198B (zh) 2013-11-08 2018-09-21 橘生药品工业株式会社 羧甲基哌啶衍生物
JP6963896B2 (ja) 2013-11-12 2021-11-10 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
RU2691136C2 (ru) 2014-11-18 2019-06-11 Вертекс Фармасьютикалз Инкорпорейтед Способ проведения высокопроизводительной тестовой высокоэффективной жидкостной хроматографии
CN111741755B (zh) * 2018-02-02 2024-04-16 尤斯特拉里斯制药有限公司（以普雷舒拉纽罗作为商号） 肠胃外制剂及其用途
KR101970099B1 (ko) * 2018-02-07 2019-04-17 한국과학기술연구원 척수 손상의 예방 및 치료용 조성물
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
CA3149980A1 (en) * 2019-08-23 2021-03-04 Pierre Vankan Therapeutic methods and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745123A (en) * 1986-02-18 1988-05-17 Warner-Lambert Company Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
US5607947A (en) * 1995-02-21 1997-03-04 Eli Lilly And Company Pyrrolidinyl tachykinin receptor antagonists
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
TW382017B (en) * 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
WO1999000368A1 (en) * 1997-06-27 1999-01-07 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
RU2236402C2 (ru) * 1999-02-24 2004-09-20 Ф.Хоффманн-Ля Рош Аг Производные 3-фенилпиридина и фармацевтическая композиция на их основе
PT1394150E (pt) * 1999-02-24 2011-02-17 Hoffmann La Roche Derivados de 4-fenilpiridina e a sua utilização como antagonistas dos receptores de nc-1
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
EP1103545B1 (en) * 1999-11-29 2003-11-05 F. Hoffmann-La Roche Ag 2-(3,5-Bis-trifluoromethyl-phenyl)-N-methyl-N-(6-morpholin-4-yl-4-o-tolyl-pyridin-3-yl)-isobutyramide
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment

Also Published As

Publication number Publication date
CA2451566C (en) 2013-09-10
IL159350A0 (en) 2004-06-01
CA2451566A1 (en) 2003-01-23
WO2003006016A2 (en) 2003-01-23
AR037008A1 (es) 2004-10-20
US20030083345A1 (en) 2003-05-01
HUP0401210A2 (hu) 2004-10-28
US20060247240A1 (en) 2006-11-02
NO20040057L (no) 2004-01-07
WO2003006016A3 (en) 2003-07-31
BR0210893A (pt) 2004-06-22
HK1068266A1 (en) 2005-04-29
HUP0401210A3 (en) 2011-07-28
CN100346789C (zh) 2007-11-07
PA8549901A1 (es) 2003-01-24
RU2304435C2 (ru) 2007-08-20
NO332847B1 (no) 2013-01-21
EP1621195A2 (en) 2006-02-01
GT200200143A (es) 2002-11-11
PL211246B1 (pl) 2012-04-30
AU2002328837B2 (en) 2005-05-05
MXPA04000278A (es) 2004-05-04
ZA200400138B (en) 2005-06-29
UY27374A1 (es) 2003-03-31
PL369535A1 (en) 2005-05-02
NZ530107A (en) 2006-01-27
PE20030238A1 (es) 2003-03-19
EP1406618A2 (en) 2004-04-14
CN1523988A (zh) 2004-08-25
US20110053954A1 (en) 2011-03-03
JP2004536119A (ja) 2004-12-02
KR100589106B1 (ko) 2006-06-14
EP1621195A3 (en) 2010-01-06
KR20040029362A (ko) 2004-04-06
RU2004102397A (ru) 2005-04-20

Similar Documents

Publication Publication Date Title
HRP20031071A2 (en) Use of nk-1 receptor antagonists for the treatment of brain, spinal or nerve injury
IL150548A0 (en) Brain, spinal and nerve injury treatment
AP2004002982A0 (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain.
EP1420854A4 (en) TREATMENT OF NEUROPSYCHIATRIC DISORDERS BY NERVE STIMULATION NEAR THE DIAPHRAGM
EP1434801A4 (en) TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
PL363907A1 (en) Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
AU2003249983A8 (en) Piperidines useful for the treatment of central nervous system disorders
IL176581A0 (en) Immunomodulatory compounds for the treatment of central nervous system disorders
HK1152243A1 (en) Vegf for use in the treatment of central nervous system disorders vegf
IL160483A0 (en) Treatment of disorders by unidirectional nerve stimulation
SI1474416T1 (sl) Derivati dihidrobenzodiazepin-2-ona za zdravljenje nevroloskih motenj
GB0428462D0 (en) Spinal cord stimulation as treatment for functional bowel disorders
AU2002356525A1 (en) Substituted amines for the treatment of neurological disorders
ZA200402514B (en) 4[Piperidin-4-yliden-(3-carbamoylphenyl)methyl]benzamide derivatives and their use for the treatment of pain, spinal injuries or gastrointestinal disorders.
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
AU2003290059A8 (en) Use of cd137 antagonists for the treatment of tumors
IL162475A0 (en) Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
IL162053A0 (en) Method for the treatment of bone disorders
AU2003245995A8 (en) Use of gaba-c receptor antagonists for the treatment of myopia
IL218891A0 (en) Apparatus for treatment of disorders by unidirectional nerve stimulation
PL374077A1 (en) Use of 5-ht2 receptor antagonists for the treatment of sleep disorders
GB0324283D0 (en) Therapeutic agents for the treatment of bone disorders
GB0305343D0 (en) Therapeutic agents for the treatment of bone disorders
GB0317241D0 (en) Therapeutic agents for the treatment of bone disorders

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20070628

Year of fee payment: 6

OBST Application withdrawn